miR-146a/b在Hep3B细胞中的表达及上下游调控机制探讨

doi:DOI:10.13523/j.cb.20161202

中国生物工程杂志

2016, Vol. 36

Issue (12): 8-14 DOI: DOI:10.13523/j.cb.20161202

研究报告

miR-146a/b在Hep3B细胞中的表达及上下游调控机制探讨

董建一, 王欣欣, 王康伟, 陈军, 李慧玲, 王福金, 王爱国, 王靖宇

大连医科大学实验动物中心大连 116044

MiR-146a/b Expression and Related up and Down-stream Regulatory Mechanisms in Human Hepatoma Cells

DONG Jian-yi, WANG Xin-xin, WANG Kang-wei, CHEN Jun, LI Hui-ling, WANG Fu-jin, WANG Ai-guo, WANG Jing-yu

Laboratory Animal Center, Dalian Medical University, Dalian 116044, China

全文: PDF(815 KB) HTML

摘要：

目的：探究miR-146a/b在Hep3B的表达及其上游调控机制和下游靶标蛋白。方法：MTT法检测人正常肝细胞株LO2和人肝癌细胞株HepG2、Hep3B的增殖活性。分别提取3个细胞的总RNA和蛋白，应用RT-qPCR和蛋白印记法分别检测细胞株中miR-146a/b的表达和细胞外调节激酶1/2（ERK）、磷酸化ERK 1/2（p-ERK1/2）、磷酸化蛋白激酶B（p-AKT）、NF-κB抑制蛋白α亚基（IκBα）、白介素1受体关联激酶1（IRAK1）、肿瘤坏死因子受体相关蛋白6（TRAF6）的蛋白水平。用抑制剂分别抑制Hep3B细胞PI3K、AKT、ERK、NF-κB信号分子的活性并检测miR-146a/b的表达水平及IRAK1、TRAF6的蛋白水平。结果Hep3B细胞增殖活力和miR-146a/b表达水平显著高于LO2和HepG2（P<0.01）。蛋白印记结果显示，以LO2为对照组，Hep3B细胞的p-ERK1、ERK1、p-AKT、IκB的蛋白水平明显升高，分别为LO2的10.87、24.68、6.67和1.92倍；IRAK1、TRAF6的蛋白水平明显降低，分别为LO2的0.23和0.003倍。与LO2细胞相比，HepG2细胞的IκB和IRAK1蛋白表达明显升高，分别为LO2的4.46和2.69倍。抑制Hep3B细胞的PI3K和AKT活性12 h和24 h，miR-146a和miR-146b的表达水平显著降低（P<0.05）；抑制ERK和NF-κB的活性12 h和24 h，miR-146a/b的表达水平没有显著变化。抑制PI3K、AKT、ERK、NF-κB信号通路活性均可上调TRAF6和下调IRAK1的蛋白表达水平。结论：在恶化程度较高的Hep3B细胞中，PI3K/AKT可通过上调miR-146a/b的表达进而下调TRAF6的蛋白水平，这一机制为肝肿瘤发生发展的机理研究提供了重要线索。

关键词： miR-146a/b; PI3K/AKT; IRAK1; TRAF6

Abstract:

Objective: To investigate the expression of miR-146a/b and related upstream regulatory mechanisms and downstream target proteins in human heptoma cells. Methods: The proliferation activities of the normal human hepatocyte cell line LO2 and human heptoma cell lines HepG2 and Hep3B were assayed by MTT. Total RNA and protein were extracted from the cells and the miR-146a/b levels were detected by RT-qPCR and protein levels of p-ERK, ERK, p-AKT, IκB, IRAK1, and TRAF6 were detected by Western blot. The activities of PI3K, ERK, AKT, and NF-κB signaling molecules were inhibited in Hep3B cells, respectively, and the corresponding expression levels of miR-146a/b and protein levels of IRAK1 and TRAF6 were detected. Results: The order of proliferation activities were Hep3B > HepG2 > LO2. Compared to LO2 and HepG2 cells, the expression levels of miR-146a and miR-146b increased significantly in Hep3B cells (P<0.01). Compared to LO2 cells, the expression levels of miR-146a decreased significantly in HepG2 cells (P<0.001). In Hep3B cells, the protein levels of p-ERK1, ERK1, p-AKT, IκB increased 10.87, 24.68, 6.67 and 1.92 times of LO2 cells, respectively; and the protein levels of IRAK1 and TRAF6 decreased 0.23 and 0.003 times of LO2 cells, respectively. In HepG2 cells, the protein levels of IκB and IRAK1 increased 4.46 and 2.69 times of LO2 cells, respectively. In Hep3B cells, inhibition of PI3K and AKT activity significantly reduced the expression levels of miR-146a/b at 12 h and 24 h (P<0.05). Inhibition of ERK and NF-κB activity had no effect on the expression levels of miR-146a/b at 12 h and 24 h. Inhibition of PI3K, AKT, ERK, and NF-κB signaling molecular activities elevated the TRAF6 and decreased the IRAK1 protein levels. Conclusions: PI3K/AKT signaling pathway down-regulates the protein levels of TRAF6 by up-regulating the expression levels of miR-146a/b in Hep3B cells. This mechanism provides valuable clue for researches on hepatocellular carcinogensis.

Key words: IRAK1 miR-146a/b PI3K/AKT TRAF6

收稿日期: 2016-05-30 出版日期: 2016-12-25

ZTFLH:

R735.7

基金资助:

国家自然科学基金资助项目（30872950）

通讯作者: 王靖宇, 王爱国 E-mail: wangjingyus@163.com;wangaiguo@hotmail.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

董建一, 王欣欣, 王康伟, 陈军, 李慧玲, 王福金, 王爱国, 王靖宇. miR-146a/b在Hep3B细胞中的表达及上下游调控机制探讨[J]. 中国生物工程杂志, 2016, 36(12): 8-14.

DONG Jian-yi, WANG Xin-xin, WANG Kang-wei, CHEN Jun, LI Hui-ling, WANG Fu-jin, WANG Ai-guo, WANG Jing-yu. MiR-146a/b Expression and Related up and Down-stream Regulatory Mechanisms in Human Hepatoma Cells. China Biotechnology, 2016, 36(12): 8-14.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/DOI:10.13523/j.cb.20161202 或 https://manu60.magtech.com.cn/biotech/CN/Y2016/V36/I12/8

[1] O'Donnell K A, Wentzel E A, Zeller K I, et al., c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435(7043):839-843.
[2] Lee Y S, Dutta A. MicroRNAs in cancer. Annu Rev Pathol, 2009, 4:199-227.
[3] Taylor M A, Schiemann W P. Therapeutic opportunities for targeting microRNAs in cancer. Mol Cell Ther, 2014, 2(30):1-13.
[4] Yang Y, Wang J K. The functional analysis of MicroRNAs involved in NF-kappaB signaling. Eur Rev Med Pharmacol Sci, 2016, 20(9):1764-1774.
[5] Park H, Huang X, Lu C, et al., MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins. J Biol Chem, 2015, 290(5):2831-2841.
[6] Liu R, Liu C, Chen D, et al. FOXP3 controls an miR-146/NF-kappaB negative feedback loop that inhibits apoptosis in breast cancer cells. Cancer Res, 2015,75(8):1703-1713.
[7] Liu R, Yi B, Wei S, et al. FOXP3-miR-146-NF-kappaB axis and therapy for precancerous lesions in prostate. Cancer Res, 2015, 75(8):1714-1724.
[8] Sun M, Fang S, Li W, et al. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma. Cancer Biomark, 2015, 15(1):33-40.
[9] Czajka A A, Wojcicka A, Kubiak A, et al. Family of microRNA-146 regulates RARbeta in papillary thyroid carcinoma. PLoS One, 2016, 11(3):e0151968.
[10] Hung P S, Liu C J, Chou C S, et al. miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes. PLoS One,2013,8(11):e79926.
[11] Jopling C L, Yi M, Lancaster A M, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005, 309(5740):1577-1581.
[12] Huang Y S, Dai Y, Yu X F, et al. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol, 2008, 23(1):87-94.
[13] Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci, 2011,120(5):183-193.
[14] Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog, 2013, 52(4):297-303.
[15] Katayama Y, Maeda M, Miyaguchi K, et al. Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling. Oncol Lett, 2012, 4(4):817-823.
[16] Zhang Z, Zhang Y, Sun X X, et al. microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer, 2015, 14:5.
[17] Cong N, Chen H, Bu W Z, et al. miR-146a G>C polymorphisms and risk of hepatocellular carcinoma in a Chinese population. Tumour Biol, 2014, 35(6):5669-5673.
[18] Martini M, De Santis M C, Braccini L, et al. PI3K/AKT signaling pathway and cancer:an updated review. Ann Med, 2014, 46(6):372-383.
[19] Knowles B B, Howe C C, Aden D P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science, 1980, 209(4455):497-499.

[1]	叶雨辰, 赵俊龙, 王琳, 段娟丽, 高春辰, 秦鸿雁, 窦科峰. EGFP-Luc-Hepa1-6细胞系的构建及其在小鼠肝癌模型中的应用[J]. 中国生物工程杂志, 2015, 35(5): 1-7.
[2]	陈光辉, 刘预, 孔飞飞, 邱欣欣, 成凤, 匡文斌, 李朴, 涂植光. *shRNA靶向干扰COX-2抑制人肝癌裸鼠皮下移植瘤及其血管生成*[J]. 中国生物工程杂志, 2011, 31(03): 29-34.

Viewed

Full text

Abstract

Cited

Shared

Discussed